Financial reports
ARS
2023 FY
Annual report to shareholders
25 Apr 24
10-K
2023 FY
Annual report
28 Feb 24
10-Q
2023 Q3
Quarterly report
6 Nov 23
10-Q
2023 Q2
Quarterly report
3 Aug 23
10-Q
2023 Q1
Quarterly report
9 May 23
ARS
2022 FY
Annual report to shareholders
27 Apr 23
10-K
2022 FY
Annual report
7 Mar 23
10-Q
2022 Q3
Quarterly report
8 Nov 22
10-Q
2022 Q2
Quarterly report
4 Aug 22
10-Q
2022 Q1
Quarterly report
4 May 22
Current reports
8-K
Departure of Directors or Certain Officers
2 Apr 24
8-K
Other Events
13 Mar 24
8-K
Voyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
28 Feb 24
8-K
Voyager Therapeutics Announces Pricing of Public Offering
8 Jan 24
8-K
Entry into a Material Definitive Agreement
2 Jan 24
8-K
Voyager Therapeutics Announces Selection of Development Candidate for SOD1 Amyotrophic Lateral Sclerosis Gene Therapy Program
6 Dec 23
8-K
Voyager Therapeutics Reports Third Quarter 2023 Financial and Operating Results
6 Nov 23
8-K
Entry into a Material Definitive Agreement
16 Aug 23
8-K
Voyager Therapeutics Reports Second Quarter 2023 Financial and Operating Results
3 Aug 23
8-K
Other Events
10 Jul 23
Registration and prospectus
S-8
Registration of securities for employees
28 Feb 24
D
$20.00 mm in equity, sold $20.00 mm, 1 investor
17 Jan 24
424B5
Prospectus supplement for primary offering
8 Jan 24
424B5
Prospectus supplement for primary offering
4 Jan 24
S-8
Registration of securities for employees
7 Mar 23
D
$39.03 mm in equity, sold $39.03 mm, 1 investor
3 Mar 23
424B3
Prospectus supplement
15 Nov 22
S-3
Shelf registration
8 Nov 22
S-8
Registration of securities for employees
8 Mar 22
S-8
Registration of securities for employees
26 Feb 21
Proxies
DEFA14A
Additional proxy soliciting materials
25 Apr 24
DEF 14A
Definitive proxy
25 Apr 24
DEFA14A
Additional proxy soliciting materials
9 May 23
DEFA14A
Additional proxy soliciting materials
27 Apr 23
DEF 14A
Definitive proxy
27 Apr 23
DEFA14A
Additional proxy soliciting materials
21 Apr 22
DEF 14A
Definitive proxy
21 Apr 22
DEFA14A
Additional proxy soliciting materials
19 May 21
DEF 14A
Definitive proxy
22 Apr 21
DEF 14A
Definitive proxy
22 Apr 20
Other
EFFECT
Notice of effectiveness
16 Nov 22
CORRESP
Correspondence with SEC
10 Nov 22
UPLOAD
Letter from SEC
9 Nov 22
CT ORDER
Confidential treatment order
25 Feb 22
SEC STAFF
SEC staff action: Order
19 Apr 21
SEC STAFF
SEC staff action: Order
22 Mar 21
EFFECT
Notice of effectiveness
3 Dec 19
CORRESP
Correspondence with SEC
27 Nov 19
CORRESP
Correspondence with SEC
22 Nov 19
UPLOAD
Letter from SEC
19 Nov 19
Ownership
4
Toby Ferguson
3 Apr 24
4
Robin Swartz
3 Apr 24
4
Alfred Sandrock
3 Apr 24
144
Notice of proposed sale of securities
2 Apr 24
144
Notice of proposed sale of securities
2 Apr 24
4
Toby Ferguson
26 Mar 24
3
Toby Ferguson
26 Mar 24
4
Robin Swartz
22 Feb 24
4
Alfred Sandrock
22 Feb 24
4
PETER P. PFREUNDSCHUH
22 Feb 24